Yael Cohen, MD, on Entering an Era of CAR T-Cell Therapy for Myeloma

Video

Yael Cohen, MD, sat down with CancerNetwork® to discuss how the multiple myeloma space is entering into an era of CAR T-cell therapy.

In an interview with CancerNetwork®, Yael Cohen, MD, a senior physician in the Department of Hematology at Tel-Aviv Sourasky Medical Center, discussed how findings from the phase 2 CARTITUDE-2 trial (NCT04133636), examining ciltacabtagene autoleucel (cilta-cel) in lenalidomide (Revlimid)–refractory multiple myeloma, may be indicative of the space entering an era of CAR T-cell therapies.

Transcript:

We are on the verge of a new era for myeloma because [cilta-cel] is a very potent therapy. Certainly, we will have to learn how to use it and for which patients. There are challenges with CAR T therapy, [logistically and] it's also a very expensive therapy; thought would have to be given to this, as well. Our hope is that treating patients earlier in their disease course, perhaps when their T cells are less exhausted and their disease might be not as anaplastic, that we will [provide] cure for some of the patients. [It's] early in the game, but certainly [with] the very deep responses and [minimal residual disease] negativity, perhaps for some patients, we will get there.

Reference

Cohen YC, Cohen AD, Delforge M, et al. Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, in lenalidomide-refractory patients with progressive multiple myeloma after 1-3 prior lines of therapy: updated results from CARTITUDE-2. Presented at: 2021 ASH Annual Meeting; December 11-13, 2021; Atlanta, GA. Poster 3866.

Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
Related Content